Native Antigen Company expands into new development and production facilities
Expansion doubles manufacturing capacity and includes the introduction of new facilities.
The Native Antigen Company (NAC) has relocated into larger facilities, in Oxfordshire, UK. The new building has purpose-built laboratories and doubles the company’s manufacturing capacity. This will increase the speed of new product development within NAC’s core business of infectious disease antigens and antibodies. The new laboratory space also enables NAC to add custom immunoassays to its offering to support customer’s ELISA assay and lateral flow device requirements.
The new suite of laboratories has been established to satisfy increasing commercial demands and accommodate NAC’s growing R&D pipeline. The move facilitates the expansion of the Company’s custom services for recombinant protein production, based on its proprietary mammalian cell expression system. The HEK293 expression system used at NAC has been used to prepare a wide range of complex recombinant proteins, that have been shown to be glycosylated and to demonstrate functional activity.
Dr Nick Roesen, Chief Scientific Officer, NAC, said: “I am delighted with the new facilities and the increased capacity that they provide. The addition of immunoassay development services will enable our customers to work with us from protein expression through to development of an immunoassay for a specific protein. In providing this new service we aim to fill the gap between small-scale R&D expression and high-end pharmaceutical-scale GMP manufacturing. We are excited to offer this to our customers, while at the same time progressing our own new product pipeline for infectious disease antigens and anitbodies.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance